Neurology Advisor (6/16, Khaja) reports a study found that “in adult patients with migraine and comorbid major depressive disorder (MDD), treatment with fremanezumab is associated with significant reductions in both monthly migraine days (MMDs) and depressive symptoms.” Researchers observed that “at week 12, compared with placebo, fremanezumab significantly reduced MMD. Moreover, a greater proportion of patients in the fremanezumab group achieved a ≥50% reduction in migraine days.” They found that fremanezumab “also yielded greater improvements in depressive symptoms” compared to placebo. Researchers concluded, “Fremanezumab was effective in a difficult to treat clinical population with migraine and comorbid major depressive disorders and may also be effective in alleviating psychiatric comorbidities, therefore reducing the cumulative burden on patients.” The study was published in JAMA Neurology. (SOURCE: APA Headlines)